meRfi®-GM
Crohn's disease (CD)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Crohn's disease (CD) is a chronic, relapsing inflammatory bowel disease of the human intestine resulting in significant organ damage and reduced quality of life.
Wu & Shen 2020 Front. Immunol. 11: 554880
Dell’Avalle et al. 2022 Expert Opin. Investig. Drugs 31: 145-161
Crohn’s disease (CD) can affect any part of the GI tract from the oral cavity to the perianal area
10-30% Is Familial
Typical clinical scenario: abdominal pain, chronic diarrhea, weight loss, and fatigue.
CD is characterized by segmental transmural inflammation of the intestinal mucosa that may occur anywhere in the [gast…
References (Sources)
- Crohn’s disease
- Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study
- Filgotinib for the treatment of Crohn’s disease
- Gene-environment interactions in chronic inflammatory disease
- Genetic architecture of the inflammatory bowel diseases across East Asian and European ancestries
- Post-operative recurrence in Crohn’s disease. Critical analysis of potential risk factors.
- Understanding and Preventing the Global Increase of Inflammatory Bowel Disease